-
公开(公告)号：US20230398238A1
公开(公告)日：2023-12-14
申请号：US18455407
申请日：2023-08-24
Applicant: Texas Children's Hospital , Alzeca Biosciences, LLC
Inventor： Eric A. Tanifum , Xianwei Sun , Ananth V. Annapragada , Carlo Medici
IPC: A61K49/08 , C07C49/755 , C07C65/40 , C07D333/22 , A61K49/18 , A61K47/54 , A61K9/127 , A61K49/10
CPC classification number: A61K49/085 , C07C49/755 , C07C65/40 , C07D333/22 , A61K49/1812 , A61K47/542 , A61K47/545 , A61K9/1271 , A61K49/108 , A61K47/544
Abstract: A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I:
wherein X is —CH2—, —CH2—CH2—, —CHO—, or —O—CO—; Y is —CH—CH═CH— or
A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from —H, halogen, —OH, and —CH3; and R5, R6, and R7 are independently selected from —H, halogen, —OH, —OCH3, —NO2, —N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted C4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is —H, or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US11116854B2
公开(公告)日：2021-09-14
申请号：US17162126
申请日：2021-01-29
Applicant: Texas Children's Hospital
Inventor： Eric A. Tanifum , Ketankumar B. Ghaghada , Ananth V. Annapragada
Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.
-
公开(公告)号：US20220283187A1
公开(公告)日：2022-09-08
申请号：US17739031
申请日：2022-05-06
Applicant: Alzeca Biosciences, LLC , Texas Children's Hospital
Inventor： Ananth Annapragada , Qingshan Mu , Carlo Medici
IPC: G01N33/68 , C12N15/10 , C12N15/115 , C12N15/11
Abstract: Methods and compositions for detecting tau pathology are described. The compositions for detecting tau pathology comprise a targeting ligand that specifically binds to a cell surface marker of tau pathology, wherein the targeting ligand is linked to a liposome that includes an imaging agent. The compositions can be used in a method for imaging tau pathology in a subject that comprises administering to the subject an effective amount of the composition to a subject and imaging at least a portion of the subject to determine if that portion of the subject exhibits tau pathology. The compositions can also be used to detect tau pathology in biological samples obtained from a subject.
-
公开(公告)号：US20220023445A1
公开(公告)日：2022-01-27
申请号：US17403058
申请日：2021-08-16
Applicant: Texas Children's Hospital
Inventor： Eric A. Tanifum , Ketankumar B. Ghaghada , Ananth V. Annapragada
Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.
-
公开(公告)号：US20210236662A1
公开(公告)日：2021-08-05
申请号：US17162126
申请日：2021-01-29
Applicant: Texas Children's Hospital
Inventor： Eric A. Tanifum , Ketankumar B. Ghaghada , Ananth V. Annapragada
Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.
-
Patent Agency Ranking
公开(公告)号：US20200179540A1
公开(公告)日：2020-06-11
申请号：US16791068
申请日：2020-02-14
Applicant: Texas Children's Hospital
Inventor： Ananth V. Annapragada , Eric A. Tanifum , Mayank Srivastava
Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-β plaque deposits characteristic of Alzheimer's Disease.
-
公开(公告)号：US20170080111A1
公开(公告)日：2017-03-23
申请号：US15366667
申请日：2016-12-01
Applicant: Texas Children's Hospital
Inventor： Ananth Annapragada , Eric A. Tanifum , Mayank Srivastava
Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-β plaque deposits characteristic of Alzheimer's Disease.
-
公开(公告)号：US11241510B2
公开(公告)日：2022-02-08
申请号：US15827782
申请日：2017-11-30
Applicant: TEXAS CHILDREN'S HOSPITAL
Inventor： Ananth Annapragada , Eric A. Tanifum
Abstract: Readily available hydrophilic and small organofluorine moieties were condensed via “click chemistry” to generate nonionic hydrophilic fluorinated molecules with unique 19F MR signatures. These were used to fabricate stable liposome formulations for imaging various tissue types. This approach was tailored to exploit the broad spectrum of organic 19F molecular species and to generate probes with distinct 19F MRI signatures for simultaneous assessment of multiple molecular targets within the same target volume.
-
公开(公告)号：US11141495B2
公开(公告)日：2021-10-12
申请号：US16791068
申请日：2020-02-14
Applicant: Texas Children's Hospital
Inventor： Ananth V. Annapragada , Eric A. Tanifum , Mayank Srivastava
Abstract: Provided are aromatic compounds, phospholipid-polymer-aromatic conjugates comprising the aromatic compounds, and liposome compositions including the phospholipid-polymer-aromatic conjugates. The liposomal compositions may be useful for imaging of Alzheimer's Disease, for example, imaging of the amyloid-β plaque deposits characteristic of Alzheimer's Disease.
-
公开(公告)号：US20210252170A1
公开(公告)日：2021-08-19
申请号：US17175359
申请日：2021-02-12
Applicant: Texas Children's Hospital , Alzeca Biosciences, LLC
Inventor： Eric A. Tanifum , Xianwei Sun , Ananth V. Annapragada , Carlo Medici
IPC: A61K49/10 , C07C49/577 , C07C65/40 , C07D333/22 , A61K49/18 , A61K47/60 , A61K49/08 , A61K47/54
Abstract: A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: wherein X is —CH2—, —CH2—CH2—, —CHO—, or —O—CO—; Y is —CH—CH═CH— or A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from —H, halogen, —OH, and —CH3; and R5, R6, and R7 are independently selected from —H, halogen, —OH, —OCH3, —NO2, —N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted C4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is —H, or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.015 seconds)
